J. Barrett

发表

COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

M. Drayson, R. Sadler, K. Ramasamy, 2021, British journal of haematology.

WS2_1 The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)

J. Barrett, N. Basu, A. Salama, 2017 .

Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia

C. Cooper, R. Eastell, P. Wordsworth, 2016, Orphanet Journal of Rare Diseases.

COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

M. Drayson, R. Sadler, K. Ramasamy, 2021, medRxiv.

Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response

N. Gray, M. Drayson, R. Sadler, 2021, medRxiv.

The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project

Kazuto Kato, J. Kaye, Chisato Yamasaki, 2021, Research Involvement and Engagement.

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study

J. Barrett, N. Basu, A. Salama, 2021, Arthritis & rheumatology.

OP0021 Draft classification criteria for the anca associated vasculitides

P. Merkel, J. Barrett, A. Judge, 2018, WEDNESDAY, 13 JUNE 2018.

factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study

J. Barrett, N. Basu, A. Salama, 2021 .